S100 Calcium Binding Protein A16 Promotes the Proliferation and Invasive Progression in Lung Adenocarcinoma

Abstract

Abstract: Objective To investigate the effect of the expression level of S100 calcium-binding protein A16 in lung adenocarcinoma (LUAD) tissues on patient prognosis, and the effect of overexpression of S100A16 on the malignant behavior of lung cancer cells. Methods The expression level of S100A16 in lung cancer microarray was detected by immunohistochemistry. According to the expression level of S100A16 in tumor tissues, immunohistochemical scores were performed to statistically analyze the relationship between S100A16 expression and clinicopathological parameters and patient prognosis. The gene expression of S100A16 in lung adenocarcinoma tissues and normal tissues was analyzed by GEPIA database. After S100A16 was knocked down in lung cancer cell line, cell migration and invasion ability were detected by cell scratch assay and Transwell assay, and the proliferation ability of lung cancer cells was detected by Edu assay. Results Immunohistochemical results showed that the expression level of S100A16 was significantly up-regulated in tumour tissues compared to paraneoplastic tissues, and the elevated level of S100A16 expression was associated with lymph node metastasis, tumour stage and distant organ metastasis (P<0.05), but not related to differentiation degree, age, or gender (P>0.05). Survival analysis showed that the higher the level of S100A16 expression in tumour tissue, the worse the prognosis of patients (P<0.001). The vitro experiment showed that inhibition of S100A16 expression suppressed the proliferation and invasive ability of tumour cells (P<0.001). Conclusion The expression level of S100A16 in LADC tumor tissues is elevated, and its expression level is related to clinicopathological parameters. Patients with elevated S100A16 expression tend to have a poorer prognosis. The expression level of S100A16 can regulate the proliferation and invasion of tumor cells.

Key words: S100A16, lung adenocarcinoma, clinical pathology parameters, tumor cell invasion and proliferation

摘要： 目的探讨S100钙结合蛋白A16在肺腺癌（LUAD）组织中的表达水平对患者预后的影响,以及敲低S100A16对肺癌细胞增殖和侵袭的影响。方法采用免疫组化技术检测肺癌组织芯片中S100A16的表达水平。根据S100A16在肿瘤组织中的表达水平进行免疫组化评分,统计分析S100A16的表达与临床病理参数及患者预后的关系。通过GEPIA2.0数据库分析S100A16在肺腺癌组织和正常组织中的基因表达,将S100A16在肺癌细胞系敲低后,通过细胞划痕实验和Transwell实验检测细胞迁移和侵袭能力,通过EdU实验检测肺癌细胞的增殖能力。结果免疫组化结果显示,与癌旁组织相比,肿瘤组织中S100A16表达水平显著上调,并且S100A16表达水平升高与淋巴结转移、肿瘤分期、远处器官转移有关（P<0.05）,而与分化程度、年龄、性别无关（P>0.05）。生存分析显示肿瘤组织中S100A16表达水平越高,患者的预后越差（P<0.001）。体外实验显示,抑制S100A16的表达,则遏制肿瘤细胞的增殖和侵袭能力（P<0.001）。结论在肺腺癌组织中S100A16的表达水平升高,其表达水平与临床病理参数有关。S100A16的表达水平升高的患者预后往往较差。S100A16的表达水平可以调控肿瘤细胞的增殖和侵袭能力。

关键词: S100A16, 肺腺癌, 临床病理参数, 肿瘤细胞侵袭和增殖

CLC Number:

R734.2

WANG Hui-jie, SUN Zhen-gui, ZHAO Wen-ying, GENG Biao. S100 Calcium Binding Protein A16 Promotes the Proliferation and Invasive Progression in Lung Adenocarcinoma[J]. Journal of Chengde Medical University, 2023, 40(5): 389-394.

王会杰, 孙珍贵, 赵文英, 耿彪. S100钙结合蛋白A16促进肺腺癌增殖和侵袭进展的研究[J]. 承德医学院学报, 2023, 40(5): 389-394.

References

[1] Chen X, Cao X, Xiao W, et al.PRDX5 as a novel binding partner in Nrf2-mediated NSCLC progression under oxidative stress[J]. Aging (Albany NY), 2020, 12(1): 122-137.
[2] Socinski MA, Obasaju C, Gandara D, et al.Clinicopathologic Features of Advanced Squamous NSCLC[J]. J Thorac Oncol, 2016, 11(9): 1411-1422.
[3] Xu P, Jiang L, Yang Y, et al.PAQR4 promotes chemoresistance in non-small cell lung cancer through inhibiting Nrf2 protein degradation[J]. Theranostics, 2020, 10(8): 3767-3778.
[4] Piyada Sitthideatphaiboon, Ana Galan-Cobo, Marcelo V, et al.STK11/LKB1 Mutations in NSCLC Are Associated with KEAP1/NRF2-Dependent Radiotherapy Resistance Targetable by Glutaminase Inhibition[J]. Clin Cancer Res, 2021, 27(6): 1720-1733.
[5] Fang D, Zhang C, Xu P, et al.S100A16 promotes metastasis and progression of pancreatic cancer through FGF19-mediated AKT and ERK1/2 pathways[J]. Cell Biol Toxicol, 2021, 37(4): 555-571.
[6] Saiki Y, Horii A.Multiple functions of S100A10, an important cancer promoter[J]. Pathol Int, 2019, 69(11): 629-636.
[7] Donato R, Cannon BR, Sorci G, et al.Functions of S100 proteins.[J] Curr Mol Med, 2013, 13(1): 24-57.
[8] Marenholz I, Heizmann CW.S100A16, a ubiquitously expressed EF-hand protein which is up-regulated in tumors[J]. Biochem Biophys Res Commun, 2004, 313(2): 237-244.
[9] Zhu W, Xue Y, Liang C, et al.S100A16 promotes cell proliferation and metastasis via AKT and ERK cell signaling pathways in human prostate cancer[J]. Tumour Biol, 2016, 37(9): 12241-12250.
[10] Ou S, Liao Y, Shi J, et al.S100A16 suppresses the proliferation, migration and invasion of colorectal cancer cells in part via the JNK/p38 MAPK pathway[J]. Mol Med Rep, 2021, 23(2): 164.
[11] Jin R, Zhao A, Han S, et al.The interaction of S100A16 and GRP78 actives endoplasmic reticulum stress-mediated through the IRE1α/XBP1 pathway in renal tubulointerstitial fibrosis[J]. Cell Death Dis, 2021, 12(10): 942.
[12] Zhou W, Pan H, Xia T, et al.Up-regulation of S100A16 expression promotes epithelial-mesenchymal transition via Notch1 pathway in breast cancer[J]. J Biomed Sci, 2014, 21(1): 97.
[13] He K, Wen XY, Li AL, et al.Serum peptidome variations in a healthy population: reference to identify cancer-specific peptides[J]. PLoS One, 2013, 8(5): e63724.
[14] Hernández JL, Padilla L, Dakhel S, et al.Therapeutic targeting of tumor growth and angiogenesis with a novel anti-S100A4 monoclonal antibody[J]. PLoS One, 2013, 8(9): e72480.
[15] Chen H, Xu C, Jin Q, et al.S100 protein family in human cancer[J]. Am J Cancer Res, 2014, 4(2): 89-115.
[16] Gonzalez LL, Garrie K, Turner MD.Role of S100 proteins in health and disease[J]. Biochim Biophys Acta Mol Cell Res, 2020, 1867(6): 118677.
[17] Bresnick AR, Weber DJ, Zimmer DB.S100 proteins in cancer[J]. Nat Rev Cancer, 2015, 15(2): 96-109.
[18] Liu M, Wang Y, Miettinen JJ, et al.S100 Calcium Binding Protein Family Members Associate With Poor Patient Outcome and Response to Proteasome Inhibition in Multiple Myeloma[J]. Front Cell Dev Biol, 2021, 9: 723016.
[19] Miao S, Qiu T, Zhao Y, et al.Overexpression of S100A13 protein is associated with tumor angiogenesis and poor survival in patients with early-stage non-small cell lung cancer[J]. Thorac Cancer, 2018, 9(9): 1136-1144.
[20] Liu L, Qi L, Knifley T, et al.S100A4 alters metabolism and promotes invasion of lung cancer cells by up-regulating mitochondrial complex I protein NDUFS2[J]. J Biol Chem, 2019, 294(18): 7516-7527.
[21] Heizmann CW, Fritz G, Schäfer BW.S100 proteins: structure, functions and pathology[J]. Front Biosci, 2002, 7: d1356-d1368.
[22] Wang C, Zhu X, Li A, et al.S100A16 regulated by Snail promotes the chemoresistance of nonmuscle invasive bladder cancer through the AKT/Bcl-2 pathway[J]. Cancer Manag Res, 2019, 11: 2449-2456.
[23] Ridinger K, Ilg EC, Niggli FK, et al.Clustered organization of S100 genes in human and mouse[J]. Biochim Biophys Acta, 1998, 1448(2): 254-263.
[24] Chen D, Luo L, Liang C.Aberrant S100A16 expression might be an independent prognostic indicator of unfavorable survival in non-small cell lung adenocarcinoma[J]. PLoS One, 2018, 13(5): e0197402.
[25] Du B, Shim JS.Targeting Epithelial-Mesenchymal Transition (EMT) to Overcome Drug Resistance in Cancer[J]. Molecules, 2016, 21(7): 965.
[26] Wang N, Wang R, Tang J, et al.Calbindin S100A16 Promotes Renal Cell Carcinoma Progression and Angiogenesis via the VEGF/VEGFR2 Signaling Pathway[J]. Contrast Media Mol Imaging, 2022, 2022: 5602011.
[27] Zhang H, Yang Y, Ma X, et al.S100A16 Regulates HeLa Cell through the Phosphatidylinositol 3 Kinase (PI3K)/AKT Signaling Pathway[J]. Med Sci Monit, 2020, 26: e919757.